Trial Profile
Efficacy of Twice Daily Applications of LEO 124249 Ointment 30mg/g for 12 Weeks to Subjects With Alopecia Areata
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2023
Price :
$35
*
At a glance
- Drugs Delgocitinib (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors LEO Pharma
- 01 Mar 2023 Primary endpoint (Change in Severity of Alopecia Areata Tool (SALT) Score) has not been met as per Results published in the Archives of Dermatological Research.
- 01 Mar 2023 Results assessing safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata published in the Archives of Dermatological Research
- 15 Dec 2016 Status changed from recruiting to completed.